These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38618204)

  • 21. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
    Papp K; Warren RB; Green L; Reich K; Langley RG; Paul C; Asahina A; Johnson L; Arora V; Osuntokun O; Lebwohl M
    Lancet Rheumatol; 2023 Sep; 5(9):e542-e552. PubMed ID: 38251498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial.
    Dauvilliers Y; Lecendreux M; Lammers GJ; Franco P; Poluektov M; Caussé C; Lecomte I; Lecomte JM; Lehert P; Schwartz JC; Plazzi G
    Lancet Neurol; 2023 Apr; 22(4):303-311. PubMed ID: 36931805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
    Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
    Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial.
    Zhang Y; Yan B; Zhu Z; Wang X; Song X; Zhu D; Ma T; Zhang Y; Meng C; Wang G; Wang C; Zhang L
    EClinicalMedicine; 2024 Mar; 69():102467. PubMed ID: 38356731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
    Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
    Reilmann R; Anderson KE; Feigin A; Tabrizi SJ; Leavitt BR; Stout JC; Piccini P; Schubert R; Loupe P; Wickenberg A; Borowsky B; Rynkowski G; Volkinshtein R; Li T; Savola JM; Hayden M; Gordon MF;
    Lancet Neurol; 2024 Mar; 23(3):243-255. PubMed ID: 38280392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial.
    Hofbauer LC; Witvrouw R; Varga Z; Shiota N; Cremer M; Tanko LB; Rooks D; Auberson LZ; Arkuszewski M; Fretault N; Schubert-Tennigkeit AA; Papanicolaou DA; Recknor C
    Lancet Healthy Longev; 2021 May; 2(5):e263-e274. PubMed ID: 36098133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS-challenge as a first-look test for detection of primary aldosteronism in patients with treatment-resistant hypertension.
    Beger C; Karg T; Hinrichs JB; Ringe B; Haller H; Meyer BC; Limbourg FP
    Blood Press; 2023 Dec; 32(1):2179340. PubMed ID: 36803263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension.
    Verdecchia P; Calvo C; Möckel V; Keeling L; Satlin A
    Blood Press; 2007; 16(6):381-91. PubMed ID: 18058456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
    Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
    Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO.
    Parthasarathy HK; Alhashmi K; McMahon AD; Struthers AD; McInnes GT; Ford I; Connell JM; MacDonald TM
    J Hypertens; 2010 Jan; 28(1):170-7. PubMed ID: 20009770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
    Bril V; Drużdż A; Grosskreutz J; Habib AA; Mantegazza R; Sacconi S; Utsugisawa K; Vissing J; Vu T; Boehnlein M; Bozorg A; Gayfieva M; Greve B; Woltering F; Kaminski HJ;
    Lancet Neurol; 2023 May; 22(5):383-394. PubMed ID: 37059507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
    Tuttle KR; Hauske SJ; Canziani ME; Caramori ML; Cherney D; Cronin L; Heerspink HJL; Hugo C; Nangaku M; Rotter RC; Silva A; Shah SV; Sun Z; Urbach D; de Zeeuw D; Rossing P;
    Lancet; 2024 Jan; 403(10424):379-390. PubMed ID: 38109916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Cunningham S; Piedra PA; Martinon-Torres F; Szymanski H; Brackeva B; Dombrecht E; Detalle L; Fleurinck C;
    Lancet Respir Med; 2021 Jan; 9(1):21-32. PubMed ID: 33002427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.